4.7 Article

Candidaemia in internal medicine departments: the burden of a rising problem

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 19, Issue 6, Pages E281-E284

Publisher

ELSEVIER SCI LTD
DOI: 10.1111/1469-0691.12155

Keywords

Antifungal therapy; candidaemia; internal medicine ward; mortality; time

Funding

  1. Angelini
  2. Pfizer Inc.
  3. Merck Serono
  4. Novartis
  5. GlaxoSmithKline
  6. Gilead Sciences Inc.
  7. Sanofi-Aventis
  8. Teva Inc.
  9. Bayer Schering Pharma
  10. Janssen
  11. Astellas Pharma Inc.
  12. Pfizer
  13. Gilead
  14. MSD
  15. Astellas
  16. Abbott
  17. Nadirex International
  18. BMS
  19. Jansen

Ask authors/readers for more resources

Although internal medicine wards (IMWs) represent a significant reservoir of patients with candidemia, few investigators have specifically addressed the epidemiological aspects of candidaemia in this population. Of all patients hospitalized during the study period with candidaemia, 133/348 (38%) were admitted to IMWs. Variables associated with IMWs included: antibiotic therapy prior to hospitalization, urinary or central venous catheter, parenteral nutrition, tumour and age >75years. Overall, 30-day mortality in IMWs was significantly higher than that in other wards (51.1% vs. 38.2%, p<0.02). Multiple logistic regression analysis identified the administration of antifungal treatment 48h after having the first positive BC as an independent determinant of hospital mortality. Patients with candidaemia in IMWs account for a substantial proportion of patients with candidaemia and have higher mortality compared with patients in other wards.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available